V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007711 | 10005571 | 1.83 | null | null | 2017-12-25 | 2017-12-25 | Gefitinib: Cycle 3 only (PAS) | N | N | 10494769 | IDARUBICIN |
| 10007712 | 10005572 | 1.57 | 61.6 | null | 2019-11-10 | 2019-11-11 | Bevacizumab+Carbo+Pacliaxel | N | N | 10501999 | LIPOSOMAL DOXORUBICIN |
| 10007713 | 10005572 | 1.67 | 83.7 | Palliative (P) | null | 2018-10-22 | Panitumumab | 02 | N | 10501999 | CAPECITABINE + CISPLATIN + RT |
| 10007714 | 10005573 | 1.72 | 110 | Palliative (P) | 2018-04-04 | 2019-01-04 | GEMCITABINE + NAB PACLITAXEL | N | Y | 10505211 | HYDROXYCARBAMIDE |
| 10007715 | 10007761 | null | 124.2 | null | 2017-05-15 | 2017-05-17 | Eribulin | N | N | 10506839 | BENDAMUSTINE + OBINUTUZUMAB |
| 10007716 | 10005579 | 1.64 | 62.2 | Palliative (P) | 2018-05-24 | 2018-06-07 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10507543 | CISPLATIN + PEMETREXED |
| 10007717 | 10005579 | 1.66 | 96.05 | Adjuvant (A) | 2017-10-03 | 2017-10-09 | ECX | N | N | 10507543 | CAPECITABINE + CARBOPLATIN |
| 10007718 | 10005582 | 1.83 | 103 | Disease modification (D) | 2018-01-11 | 2018-01-18 | CARBOPLATIN + PACLITAXEL + RT | N | null | 10511472 | THALIDOMIDE |
| 10007719 | 10005582 | null | 79 | Palliative (P) | 2018-04-25 | 2018-06-20 | Irinotecan | null | N | 10511472 | CAPECITABINE + GEMCITABINE |
| 10007720 | 10005582 | 1.57 | 57.5 | Disease modification (D) | 2018-06-19 | 2018-07-18 | AML 19 TRIAL | 02 | N | 10511472 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10007721 | 10005584 | 1.85 | 65 | Disease modification (D) | null | 2017-06-26 | CHLVPP | N | N | 10513232 | RCEOP |
| 10007722 | 10005585 | 1.7 | 79.9 | Adjuvant (A) | 2017-10-31 | 2017-11-08 | Melphalan IV High dose | N | N | 10513781 | ERLOTINIB |
| 10007723 | 10005586 | 1.49 | 72.6 | Disease modification (D) | 2020-01-30 | 2020-02-04 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 2 | N | 10514154 | CAPECITABINE + CISPLATIN + RT |
| 10007724 | 10005587 | 1.56 | 74 | Palliative (P) | 2016-11-30 | 2016-12-13 | CAV | 02 | N | 10514736 | RCEOP |
| 10007725 | 10005587 | 1.82 | null | Curative (C) | 2018-10-05 | 2018-10-06 | OCTREOTIDE | N | N | 10514736 | CISPLATIN + GEMCITABINE |
| 10007726 | 10005588 | null | 71.6 | Palliative (P) | 2017-06-21 | 2017-06-26 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 10517788 | IRINOTECAN |
| 10007727 | 10007767 | 1.78 | 65 | Palliative (P) | 2018-06-24 | 2018-06-24 | TCX | 01 | N | 10519332 | DHAP - R |
| 10007728 | 10007767 | 0 | 85.5 | Palliative (P) | 2014-11-22 | 2016-07-03 | Pazopanib | Y | N | 10519332 | FLUOROURACIL + MITOMYCIN + RT |
| 10007729 | 10007767 | 1.77 | 79 | Curative (C) | 2018-11-01 | 2018-11-26 | ECX | N | N | 10519332 | BORTEZOMIB + THALIDOMIDE |
| 10007730 | 10005590 | 1.75 | 81 | Palliative (P) | 2015-01-01 | 2015-02-20 | Bevacizumab + Oxaliplatin +MdG | N | N | 10522394 | POMALIDOMIDE |
| 10007731 | 10005591 | null | null | Curative (C) | 2016-01-13 | 2016-01-15 | METAPHER Trial | 2 | N | 10522479 | ATG + BUSULFAN + FLUDARABINE |
| 10007732 | 10005592 | 1.5 | 86.2 | Curative (C) | 2019-01-30 | 2019-01-30 | Cisplatin + Pemetrexed | N | null | 10523571 | TRIPLE INTRATHECAL |
| 10007733 | 10005594 | 1.61 | null | null | 2019-05-02 | 2019-05-13 | DABRAFENIB | N | null | 10523571 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 10007734 | 10005595 | 1.79 | 111 | Palliative (P) | 2019-04-23 | 2019-04-24 | Bortezomib +/- Dexamethasone | 2 | N | 10524814 | BRENTUXIMAB |
| 10007735 | 10005595 | 1.78 | 98 | null | 2017-01-02 | 2017-01-06 | CHLORAMBUCIL + RITUXIMAB | 02 | null | 10524814 | CISPLATIN + RT |
| 10007736 | 10005597 | 1.77 | 93 | Disease modification (D) | 2013-11-25 | 2014-01-18 | Melphalan IV High dose | N | N | 10529619 | BORTEZOMIB |
| 10007737 | 10005597 | 1.58 | 91.2 | Palliative (P) | 2018-10-07 | 2018-10-14 | Panitumumab | N | N | 10529619 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10007738 | 10005597 | 1.72 | null | Palliative (P) | 2016-12-18 | 2016-12-18 | Bevacizumab + CAPECITABINE + OXALIPLATIN | 02 | N | 10529619 | ECF |
| 10007739 | 10005598 | 1.69 | 85.7 | Palliative (P) | 2019-10-02 | 2020-02-19 | MUK 7 TRIAL | N | null | 10531776 | CMV |
| 10007740 | 10005599 | 0 | 75.5 | Curative (C) | 2017-10-08 | 2017-11-04 | CHOEP | N | null | 10535385 | CABOZANTINIB |
| 10007741 | 10005600 | 1.53 | 80.9 | Curative (C) | 2018-12-07 | 2018-12-14 | Liposomal Doxorubicin (Caelyx) | 2 | N | 10536600 | TRIPLE INTRATHECAL |
| 10007742 | 10005600 | 1.62 | 76.3 | Adjuvant (A) | 2018-11-02 | 2018-11-02 | Venetoclax | 2 | N | 10536600 | METHOTREXATE |
| 10007743 | 10005600 | 1.66 | 69.8 | Curative (C) | 2018-08-01 | 2018-08-01 | Cisplatin + Vinorelbine (PO) | N | N | 10536600 | PALBOCICLIB |
| 10007744 | 10005601 | 0 | null | Curative (C) | 2017-10-19 | 2017-10-20 | Carboplatin + Liposomal Doxorubicin | N | null | 10540818 | IRINOTECAN |
| 10007745 | 10008695 | 1.69 | 79.3 | Curative (C) | null | 2018-07-01 | IMATINIB | N | N | 10540829 | MELPHALAN |
| 10007746 | 10009056 | 1.71 | 65.1 | Disease modification (D) | 2015-08-29 | 2015-09-25 | Capecitabine (14 day) + Irinotecan | N | N | 10541201 | CABAZITAXEL |
| 10007747 | 10009056 | 1.75 | 88 | Adjuvant (A) | null | 2018-07-18 | CHOP - 21 days | null | N | 10541201 | PAZOPANIB |
| 10007748 | 10009264 | null | 58 | Disease modification (D) | 2018-09-30 | 2018-09-30 | FCR Oral - Cycle 1 | N | N | 10542103 | CARBOPLATIN + LIPOSOMAL DOX |
| 10007749 | 10009305 | 1.63 | 61.6 | Palliative (P) | 2014-06-17 | 2014-07-01 | Panitumumab | N | N | 10542759 | LIPOSOMAL DOXORUBICIN |
| 10007750 | 10009305 | 1.85 | 104.7 | Curative (C) | 2018-06-09 | 2018-06-20 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 10542759 | SUNITINIB |
| 10007751 | 10005604 | 1.71 | 50 | Palliative (P) | 2016-09-20 | 2016-10-25 | Cisplatin + Etoposide po&iv 3 day | N | N | 10544388 | RUXOLITINIB |
| 10007752 | 10005605 | 1.69 | 93.8 | Curative (C) | 2016-12-18 | 2017-01-08 | Cape+Cisplatin+Trastuzumab Main | 02 | N | 10545578 | CISPLATIN |
| 10007753 | 10005606 | 1.71 | 84.1 | Curative (C) | 2018-10-03 | 2018-10-10 | PIN TRIAL | Y | N | 10546189 | CETUXIMAB |
| 10007754 | 10005607 | 1.81 | 73.1 | Adjuvant (A) | 2017-11-14 | 2018-02-06 | CISPLATIN + RT | N | N | 10547218 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN |
| 10007755 | 10005608 | 1.58 | 83.1 | null | 2018-12-20 | 2019-01-23 | Docetaxel + Nintedanib | 01 | N | 10547434 | BORTEZOMIB |
| 10007756 | 10005609 | 1.53 | 45.3 | null | 2016-08-13 | 2016-08-20 | DABRAFENIB + TRAMETINIB | 02 | N | 10547434 | HYDROXYCARBAMIDE |
| 10007757 | 10005611 | 1.72 | 77 | Disease modification (D) | 2017-04-21 | 2017-04-28 | Cladribine (subcut) 5 days | 01 | N | 10548429 | HYDROXYCARBAMIDE |
| 10007758 | 10005612 | 1.7 | null | Curative (C) | 2015-07-18 | 2016-03-28 | CISPLATIN + VINORELBINE | 02 | null | 10548873 | FEC |
| 10007759 | 10005613 | 1.73 | 79.9 | Palliative (P) | 2017-11-07 | 2017-11-14 | Cyclophosphamide + Etoposide (PO) | N | N | 10550481 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 10007760 | 10005615 | 1.59 | 90.6 | Palliative (P) | 2019-03-06 | 2019-05-29 | Docetaxel + Nintedanib | N | N | 10553930 | CHLORAMBUCIL |